|
|
|
| |
Mr.
Lerner has been a Director of Medarex since September 8, 1995 and our
Chairman of our Board of Directors since May 19, 1997. Mr. Lerner
served as Chairman of the Board of Directors and of the Executive
Committee of Hoffmann-La Roche Inc., a pharmaceutical and healthcare
company, from January 1993 until his retirement in September 1993, and
also served as President and Chief Executive Officer of Hoffman-La
Roche from 1980 through December 1992. Mr. Lerner served for 12 years
on the Board of the Pharmaceutical Manufacturers' Association, where he
chaired the Association's FDA Issues Committee. Mr. Lerner received a
B.S. and an M.B.A. from Rutgers University. He is currently a
Distinguished Executive-in-Residence at Rutgers University Business
School. Mr. Lerner is also a director of Covance, Inc., Nektar
Therapeutics, Inc., Panacos Pharmaceuticals, Inc. and Genmab A/S, all
publicly traded healthcare companies.
Howard H. Pien, M.B.A. Mr.
Pien is our President, Chief Executive Officer and a member of the
Board of Directors. Mr. Pien joined us on June 14, 2007. Prior to
joining us, Mr. Pien was the Chairman and Chief Executive Officer and a
Director of Chiron Corporation, a biopharmaceutical company involved in
three healthcare markets: blood testing, vaccines, and
biopharmaceuticals, from April 2003 until Chiron's merger with Novartis
in April 2006. From April 2006 to June 2007, Mr. Pien performed
consulting services. He joined Chiron from GlaxoSmithKline, where he
held roles in commercial operations and general management, including
positions as the head of the international business. Mr. Pien
previously held key positions in SmithKline Beecham's pharmaceuticals
business in the United States, the United Kingdom, and North Asia,
culminating in his tenure as President, Pharmaceuticals-North America
and head of the worldwide pharmaceutical and vaccines businesses. Prior
to joining SmithKline Beecham, he worked for six years for Abbott
Laboratories and five years for Merck & Co., in positions of sales,
market research, licensing and product management. Mr. Pien is a
Massachusetts Institute of Technology graduate and received an M.B.A.
from Carnegie-Mellon University. Mr. Pien currently serves as a
director of ViroPharma Incorporated and Vanda Pharmaceuticals, Inc.,
each a publicly traded biotechnology company.
Christian S. Schade, M.B.A. Mr.
Schade is our Senior Vice President, Finance and Administration, and
Chief Financial Officer. Mr.
Schade joined us in October 2000. Prior to joining us, Mr. Schade was a
Managing Director of Merrill Lynch & Co. Mr. Schade
was employed by Merrill Lynch from March 1992 until October 2000, and
was involved in Merrill Lynch's international capital
markets and corporate funding groups. Mr. Schade is a graduate of
Princeton University and received an M.B.A. degree from the
Wharton School of the University of Pennsylvania. Mr. Schade is also a
nominee for director of Integra LifeSciences Corporation, a publicly
traded medical technology company.
Nils Lonberg, Ph.D. Dr.
Lonberg is our Senior Vice President, Scientific Director. Dr. Lonberg
joined GenPharm International,
Inc. in 1990 as a Senior Scientist and was promoted to Director,
Molecular Biology in 1994. Mr. Lonberg joined us on October 21,
1997 upon our acquisition of GenPharm. Prior to joining GenPharm, Dr.
Lonberg was a Post-Doctoral Fellow at Memorial Sloan-Kettering Cancer
Center in New York, New York. He received a Ph.D. in Biochemistry and
Molecular Biology from Harvard
University.
Ursula B. Bartels, J.D. Ms.
Bartels is our Senior Vice President, General Counsel and Secretary.
Ms. Bartels joined us in October 2007. Prior to joining us, Ms. Bartels
was most recently Vice President, General Counsel and Secretary of
Chiron Corporation from August 2004 until April 2006, when it was
acquired by Novartis. Prior to joining Chiron, Ms. Bartels served as
Senior Vice President, General Counsel and Secretary of Boehringer
Ingelheim Corporation from 1999 through August 2004, where she was
responsible for all legal, and compliance functions for the US
businesses. Before that, she spent 11 years at SmithKline Beecham
Corporation from 1988 through 1999, serving in various capacities in
the legal department, culminating in the position of Vice President and
Associate General Counsel, Legal Operations North America. Ms. Bartels
is a graduate of Bryn Mawr College and received a J.D. from the
University of Virginia.
W. Bradford Middlekauff, J.D. Mr.
Middlekauff is our Senior Vice President, Strategy. Mr. Middlekauff
served as our Senior Vice President, General Counsel and Secretary from March
2000 through November 2007. Prior to joining us, Mr. Middlekauff was
Vice President, Business Development and General Counsel at
Algos Pharmaceutical Corporation from August 1998 until February 2000.
From September 1993 until July 1998, Mr. Middlekauff
was an associate with the law firm of Cooley Godward LLP, where he
advised life science companies on business and legal aspects of
research and development, corporate partnering and licensing, product
commercialization and corporate financing. Mr. Middlekauff is
a graduate of Brown University and received a J.D. degree from Yale Law
School.
Geoffrey M. Nichol, M.D., M.B.A. Dr. Nichol is our Senior Vice President, Product Development. Dr. Nichol joined us in September
2002. Prior to joining us, Dr. Nichol was with SmithKline Beecham Pharmaceutical (currently GlaxoSmithKline), as a Clinical
Research Physician from December 1989 through January 1996. In February, 1996, Dr. Nichol joined Novartis Pharmaceuticals as
Vice President Pulmonology, Arthritis and HRT in Clinical Research and Development, and subsequently led US Medical Affairs and
Global Project Management for Novartis. Dr. Nichol received his medical degree from Otago University Medical School in New
Zealand, and practiced pulmonary/internal medicine in New Zealand, Australia and at the Brompton Hospital and National Heart and
Lung Institute in London, England. Dr. Nichol also received an M.B.A. degree from Warwick University in the United Kingdom.
Ronald A. Pepin, Ph.D. Dr.
Pepin is our Senior Vice President, Business Development. Dr. Pepin
joined us in August 2000 as
Vice President, Business Development. Prior to joining us, Dr. Pepin
was Executive Director, External Science and Technology at the
Bristol-Myers Squibb Company. Dr. Pepin was employed by Bristol-Myers
Squibb Co. from March 1990 until July 2000 and was
responsible for the licensing of new technologies and establishing
research collaborations. Dr. Pepin is a graduate of Tufts University
and received a Ph.D. in Molecular Genetics from Georgetown University.
Patricia M. Danzon, Ph.D. Dr.
Danzon is the Celia Moh Professor, Health Care Systems, Insurance and
Risk Management at the Wharton School of the University of
Pennsylvania, where she chairs the Health Care Systems Department. She
joined Wharton in 1985. Prior to that time, Dr. Danzon held academic
and research positions at various institutions including the University
of Chicago, Stanford University, and Duke University. Dr. Danzon
received a BA from Oxford University and holds an MA and Ph.D. in
Economics from the University of Chicago. Dr. Danzon is a member of the
Institute of Medicine, and she also serves on various advisory and
editorial boards, including the Journal of Health Economics.
Robert C. Dinerstein Mr.
Dinerstein is the Global Co-Chair and New York Chair of the Financial
Institutions Practice at Greenberg Traurig, LLP, an international law
firm, where he focuses on banking and securities regulation, new
product development and international capital markets issues. Prior to
joining Greenberg Traurig Mr. Dinerstein was Vice Chairman, Americas,
and Senior Corporate Counsel of UBS Investment Bank. Mr. Dinerstein was
previously Global General Counsel of UBS Investment Bank and Executive
Vice President and General Counsel of Shearson Lehman Brothers. Prior
to those positions he was a Vice President and the General Counsel of
Citicorp's Investment Bank. He serves in varying capacities on a number
of boards and councils of professional and not for profit
organizations. Mr. Dinerstein received a B.A., cum laude, from Harvard
University and a J.D. from the University of Michigan. He also is a
graduate of the Wharton Executive Development Program.
Abhijeet J. Lele Mr.
Lele is a Managing Member of EGS Healthcare Capital Partners, a venture
capital firm that focuses on investments in medical device,
biopharmaceutical and specialty pharmaceutical companies. Prior to
joining EGS in 1998, he spent four years in the healthcare practice of
McKinsey & Company, and prior to McKinsey & Company, he held
various operating positions with Lederle Laboratories, Progenics
Pharmaceuticals, Inc. and Clontech Laboratories, Inc. He presently
serves as a director of Stereotaxis, Inc.; EP MedSystems, Inc.; and
CryoCath Technologies Inc. and is a member of the Research Development
Committee of the Juvenile Diabetes Research Foundation. Mr. Lele
received an M.A. in molecular biology from Cambridge University and an
M.B.A. with distinction from Cornell University.
Marc Rubin, M.D. Dr. Rubin is
President and CEO of Titan Pharmaceutical, Inc., a biopharmaceutical
company publicly traded on the American Stock Exchange. Prior to
joining Titan in October 2007, he was Head of Global Research and
Development for Bayer Schering Pharma and a member of the Executive
Committee of Bayer Healthcare and the Board of Management of Bayer
Schering Pharma from June 2006 to January 2007. Prior to his position
at Bayer Schering Pharma, from October 2003 through June 2006, Dr.
Rubin was a Member of the Executive Board and President of Development
for Schering AG, as well as Chairman of Schering Berlin Inc. and
President of Berlex Pharmaceuticals, a division of Schering AG. His
position included responsibility for three Global Business Units.
Before joining Schering AG, between January 1990 through September
2003, Dr. Rubin held several positions of increasing responsibility at
GlaxoSmithKline, including oversight of the development, approval and
commercial strategy for numerous programs. In 1983, Dr. Rubin completed
his clinical training in internal medicine at The Johns Hopkins
Hospital and, in 1986, subspecialty training in both oncology and
infectious disease at the National Institutes of Health, where he
remained in a senior staff position through 1989. He received his M.D.
from Cornell University Medical College and did his undergraduate work
at Cornell University.
Ronald J. Saldarini, Ph.D. Dr.
Saldarini has been a Director since May 23, 2001.
Dr. Saldarini was the President of the global vaccine business of Wyeth
Pharmaceuticals from 1986 until his retirement in 1999. After his
retirement, he founded Biological Initiatives which provides consulting
services to the vaccine/pharmaceutical industry. Dr. Saldarini is
an associate with Naimark & Associates, a hleathcare consulting
firm, and has served on several committees of the National Academy of
Sciences Institute of Medicine. He has also been a
committee member of several organizations involved in promoting
immunization and vaccine development for infectious disease. Dr.
Saldarini has a B.A. from Drew University and a Ph.D. degree in
Biochemistry and Physiology from the University of Kansas.
Charles R. Schaller Mr.
Schaller has been a Director since our inception in 1987, and was
Chairman of our Board of Directors from our inception until May 18,
1997. Since 1989, Mr. Schaller has been a chemical industry management
consultant and, until June 2002, he served as a director of AstroPower,
Inc., a publicly traded U.S. manufacturer of photovoltaic (PV)products.
Mr. Schaller is a graduate of Yale University and is a graduate of the
program in management development at Harvard Business School.
Julius A. Vida, Ph.D., M.B.A. Dr. Vida has been a Director since February 9, 1994. Since 1993,
Dr. Vida has been a self-employed pharmaceutical consultant with VIDA International Pharmaceutical
Consultants. From 1975 until his retirement in 1993, Dr. Vida held various positions at Bristol-Myers
Squibb Company and its predecessors. From 1991 to 1993, Dr. Vida was Vice President, Business
Development, Licensing and Strategic Planning, and from 1985 to 1991, he was Vice President,
Licensing. Dr. Vida graduated from Pazmany Peter University, Budapest, Hungary, holds an M.S. and a
Ph.D. in Organic Chemistry from Carnegie Institute of Technology, was a Postdoctoral Fellow at
Harvard University, and holds an M.B.A. from Columbia University. Dr. Vida is also a director of
Orphan Medical, Inc., YM Biosciences, Inc., and Spectrum Pharmaceuticals, Inc., all publicly traded
biopharmaceutical companies.
| |
